REGENERON PHARMACEUTICALS, INC.
Long book
$47.9M
Q1 2026
Positions
2
Top-10 weight
100%
concentration
Last quarter
+36.9%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsREGENERON PHARMACEUTICALS, INC. is a diversified fundamental manager, specialised in materials (99% of the long book), running a $47.9M US long book across 2 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: INTELLIA THERAPEUTICS INC, ADICET BIO INC.
Over the last 6 quarters its long book ran on average 18.2pp per quarter ahead of the S&P 500, beating the index in 5 of 6 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2024
+12.6%
Q1 2025
+21.0%
Q2 2025
+40.9%
Q3 2025
-16.0%
Q4 2025
+41.7%
Q1 2026
+36.9%
Sector allocation
Materials 99%
Healthcare 1%
Long book by quarter
What does REGENERON PHARMACEUTICALS, own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 8, 2026 | 2 | $47.9M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 6, 2026 | 2 | $33.8M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 7, 2025 | 4 | $700.4M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 1, 2025 | 4 | $1.49B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 2, 2025 | 6 | $1.23B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 7, 2025 | 6 | $1.09B | canonical | SEC ↗ |